➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
McKinsey
Harvard Business School
Merck
AstraZeneca
Dow

Last Updated: September 24, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for Sofosbuvir; Velpatasvir; Voxilaprevir

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02536313 ↗ Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination With or Without Ribavirin in Participants With Chronic Genotype 1 HCV Infection Previously Treated With a Direct Acting Antiviral Regimen Completed Gilead Sciences Phase 2 2015-07-01 This study will evaluate the efficacy, safety, and tolerability of the treatment with sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) fixed dose combination (FDC) ± ribavirin (RBV) in participants with chronic genotype 1 hepatitis C virus (HCV) infection and prior treatment experience with a direct acting antiviral as measured by the proportion of participants with sustained viral response 12 weeks after cessation of treatment (SVR12).
NCT02607735 ↗ Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir in Adults With Chronic HCV Infection Who Have Previously Received Treatment With Direct-Acting Antiviral Therapy Active, not recruiting Gilead Sciences Phase 3 2015-11-01 This study will evaluate the safety and efficacy of treatment with sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) in adults with chronic HCV infection who have previously received treatment with direct-acting antiviral therapy. Subjects randomized to placebo may be eligible for deferred treatment with active SOF/VEL/VOX.
NCT02607800 ↗ Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir and Sofosbuvir/Velpatasvir in Adults With Chronic HCV Infection Who Have Not Previously Received Treatment With Direct-Acting Antiviral Therapy Active, not recruiting Gilead Sciences Phase 3 2015-11-01 This study will evaluate the safety and efficacy of treatment with sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) and SOF/VEL in adults with chronic HCV infection who have not previously received treatment with direct-acting antiviral therapy.
NCT02639247 ↗ Safety and Efficacy of SOF/VEL/VOX FDC for 12 Weeks and SOF/VEL for 12 Weeks in DAA-Experienced Adults With Chronic HCV Infection Who Have Not Received an NS5A Inhibitor Active, not recruiting Gilead Sciences Phase 3 2015-12-01 This study will evaluate the efficacy, safety, and tolerability of treatment with sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) fixed-dose combination (FDC) for 12 weeks and of sofosbuvir/velpatasvir (SOF/VEL) FDC for 12 weeks in direct-acting antiviral (DAA)-experienced adults with chronic hepatitis C virus (HCV) infection with or without cirrhosis who have not received prior treatment with a regimen containing an inhibitor of the HCV NS5A protein.
NCT02639338 ↗ Safety and Efficacy of SOF/VEL/VOX FDC for 8 Weeks and SOF/VEL for 12 Weeks in Adults Chronic Genotype 3 HCV Infection and Cirrhosis Active, not recruiting Gilead Sciences Phase 3 2015-12-01 This study will evaluate the efficacy, safety, and tolerability of treatment with sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) fixed-dose combination (FDC) for 8 weeks and of treatment with sofosbuvir/velpatasvir (SOF/VEL) FDC for 12 weeks in adults with chronic genotype 3 hepatitis C virus (HCV) infection and cirrhosis who have not previously received treatment with direct-acting antiviral (DAA) therapy.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Sofosbuvir; Velpatasvir; Voxilaprevir

Condition Name

Condition Name for Sofosbuvir; Velpatasvir; Voxilaprevir
Intervention Trials
Hepatitis C Virus Infection 6
Hepatitis C 3
HCV Coinfection 1
Chronic Hepatitis C 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Sofosbuvir; Velpatasvir; Voxilaprevir
Intervention Trials
Hepatitis C 11
Infection 7
Virus Diseases 6
Communicable Diseases 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Sofosbuvir; Velpatasvir; Voxilaprevir

Trials by Country

Trials by Country for Sofosbuvir; Velpatasvir; Voxilaprevir
Location Trials
United States 93
Australia 14
Canada 14
New Zealand 5
Puerto Rico 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Sofosbuvir; Velpatasvir; Voxilaprevir
Location Trials
Florida 5
California 5
Texas 5
Tennessee 5
Rhode Island 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Sofosbuvir; Velpatasvir; Voxilaprevir

Clinical Trial Phase

Clinical Trial Phase for Sofosbuvir; Velpatasvir; Voxilaprevir
Clinical Trial Phase Trials
Phase 4 3
Phase 3 6
Phase 2 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Sofosbuvir; Velpatasvir; Voxilaprevir
Clinical Trial Phase Trials
Active, not recruiting 4
Not yet recruiting 4
Recruiting 3
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Sofosbuvir; Velpatasvir; Voxilaprevir

Sponsor Name

Sponsor Name for Sofosbuvir; Velpatasvir; Voxilaprevir
Sponsor Trials
Gilead Sciences 8
Johns Hopkins University 1
Helwan University 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Sofosbuvir; Velpatasvir; Voxilaprevir
Sponsor Trials
Industry 8
Other 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Boehringer Ingelheim
Harvard Business School
Express Scripts
Colorcon
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.